Cullinan Therapeutics, Inc. (CGEM)
Last updated: 2026-10-20 20:23:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Cullinan Therapeutics, Inc. (CGEM) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $14.85, with a market capitalization of $832.11M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.73 to $23.19. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$832.11M | |
$13.92 | |
$59.85 | |
$5.68 | |
$13.98 | |
542.67K | |
905.09K | |
-- | |
$23.19 | |
$6.73 | |
-- | |
-- |
Cullinan Therapeutics, Inc. (CGEM) After-Hours Stock Price
Cullinan Therapeutics, Inc. (CGEM) is trading at $14.85 in after-hours trading as of 2026-10-20 20:20:00, up 6.23% ($0.87) from the regular-session close of $13.98.
After-hours trading shows how investors are pricing CGEM after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Cullinan Therapeutics, Inc. (CGEM) 7-Day Stock Price Change
Over the past seven days, Cullinan Therapeutics, Inc. (CGEM) moved from $15.53 to $14.85, representing a decline of 4.40% ($0.68).
The stock traded between $12.77 and $15.95 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 770.25 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
CGEM 52-Week Price Position
Position in Range: 49.3%
CGEM is currently trading at $14.85, placing it 49.3% of the way from its 52-week low of $6.73 to its 52-week high of $23.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Cullinan Therapeutics, Inc. (CGEM)?
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Cullinan Therapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 109 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Cullinan Therapeutics, Inc. (CGEM) Stock on MEXC
Eligible investors can buy real shares of Cullinan Therapeutics, Inc. (CGEM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Cullinan Therapeutics, Inc. (CGEM) stock price today?
2.Is CGEM stock going up or down today?
3.What is CGEM pre-market price?
4.What is CGEM after-hours price?
5.Is CGEM stock trading now?
6.Where does CGEM sit relative to its 52-week high and low?
7.What sector is Cullinan Therapeutics, Inc. in?
8.What is Cullinan Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is CGEM valued in terms of P/E ratio and EPS?
10.Does Cullinan Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CGEM Stock Calculator
Estimate the value between CGEM shares and USD.
CGEM Shares to USD
1.00 CGEM shares = 14.846 USD
Calculations are estimates based on the latest available price and are for reference only.


